HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autologous and allogeneic bone marrow transplantation in acute myeloid leukemia in first complete remission: an update of the Genoa experience with 159 patients.

Abstract
In the attempt to evaluate the role of Autologous and Allogeneic Bone Marrow Transplantation, we have retrospectively analyzed 159 patients with Acute Myeloid Leukemia in first complete remission treated in our Unit, most of whom were referred from other Institutions. High-dose therapy was uniform and consisted of cyclophosphamide 60 mg/kg/d on two consecutive days and TBI in a single dose (10 Gy) for ABMT patients and in fractionated doses (3.3 Gy x 3 days) for BMT patients. Eight years actuarial survival was similar in two groups (52% for BMT and 49% for ABMT). The actuarial risk of relapse for BMT and ABMT was 29% and 43%, respectively. Considering that none of ABMT patients was "purged" with in vitro technique, this review seems to confirm the importance of "in vivo" purging with postremission intensification, immediately before the harvesting. Of course, more patients and a longer follow-up are needed to draw final conclusions.
AuthorsA M Carella, F Frassoni, M T van Lint, F Gualandi, D Occhini, P Carlier, N Pollicardo, E Pungolino, F Fagioli, G Santini
JournalAnnals of hematology (Ann Hematol) Vol. 64 Issue 3 Pg. 128-31 (Mar 1992) ISSN: 0939-5555 [Print] Germany
PMID1571408 (Publication Type: Journal Article)
Chemical References
  • Cyclophosphamide
Topics
  • Adolescent
  • Adult
  • Bone Marrow Transplantation
  • Child
  • Child, Preschool
  • Cyclophosphamide (therapeutic use)
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Infant
  • Italy
  • Leukemia, Myeloid, Acute (mortality, surgery, therapy)
  • Male
  • Middle Aged
  • Remission Induction
  • Retrospective Studies
  • Survival Rate
  • Transplantation, Autologous
  • Transplantation, Homologous
  • Whole-Body Irradiation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: